Should a patient with myasthenia gravis classified as Osserman class III be intubated?

Intubation of Myasthenia Gravis Osserman Class III Patients

Yes, you can and often must intubate myasthenic patients with Osserman Class III disease, but this requires specific modifications to standard intubation protocols, particularly regarding neuromuscular blocking agents (NMBAs) and close respiratory monitoring.

Understanding Osserman Class III

Osserman Class III represents acute fulminating myasthenia with rapid progression of severe symptoms and respiratory crisis 1. These patients are at high risk for myasthenic crisis, defined as respiratory failure requiring mechanical ventilation 1, 2.

When Intubation Becomes Necessary

Intubate immediately if:

• Respiratory failure develops (myasthenic crisis) 1, 2
• Maximal expiratory pressure (PEmax) falls below 40 cmH₂O 3
• Bulbar weakness causes aspiration risk 1
• Rapidly progressive symptoms threaten airway 4

Critical Modifications for Intubation

Neuromuscular Blocking Agent Considerations

Use reduced doses of non-depolarizing NMBAs with peripheral nerve stimulation (PNS) monitoring 5. Myasthenic patients have:

• Increased sensitivity to non-depolarizing agents due to reduced functional nicotinic receptors 5
• Highly variable individual responses requiring assessment before dosing 5
• Risk of prolonged blockade if standard doses are used 5

Avoid depolarizing agents (succinylcholine) entirely in myasthenic patients, as they may cause prolonged blockade, especially if patients are on cholinesterase inhibitors 1.

Alternative Intubation Approach

Consider intubation without NMBAs using a combination of:

• Propofol for induction 6
• Remifentanil for optimal intubating conditions 6
• Lidocaine to blunt airway reflexes 6

This approach has been successfully used even for rapid sequence intubation in myasthenic patients 6.

Pre-Intubation Assessment

Essential workup before intubation 4:

• Pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC)
• Creatine phosphokinase (CPK), troponin T, and ECG to rule out concurrent myocarditis
• Acetylcholine receptor (AChR) antibodies if not already confirmed
• Neurology consultation

Post-Intubation Management

Medication Adjustments

Discontinue pyridostigmine during intubation 7. Cholinesterase inhibitors should be avoided during crisis as they can worsen secretions and complicate management 1.

Avoid medications that worsen myasthenia 4:

• β-blockers
• IV magnesium
• Fluoroquinolones
• Aminoglycosides
• Macrolides

Immunotherapy During Crisis

Initiate aggressive immunotherapy for Grade 3-4 myasthenic crisis 4:

• Corticosteroids: methylprednisolone 1-2 mg/kg daily or prednisone 1-1.5 mg/kg daily
• IVIG 2 g/kg over 5 days (0.4 g/kg/day) OR
• Plasmapheresis for 5 days

Monitoring Requirements

ICU-level monitoring is mandatory 4:

• Frequent pulmonary function assessments
• Daily neurologic evaluations
• Cardiac monitoring for concurrent myocarditis
• Blood glucose monitoring (target <180 mg/dL) 5

Extubation Considerations

Predictors of successful extubation 3:

• PEmax ≥40 cmH₂O
• Adequate cough strength
• Resolution of bulbar symptoms

Consider non-invasive ventilation (NIV) post-extubation to prevent reintubation 3, 8. NIV is most successful when:

• APACHE II score <6 3
• Serum bicarbonate <30 mmol/L 3

Critical Pitfalls to Avoid

1. Never use standard NMBA doses - always reduce and monitor with PNS 5
2. Don't delay intubation in deteriorating patients - extubation failure leads to worse outcomes 3
3. Avoid continuing cholinesterase inhibitors during acute crisis 1
4. Don't overlook cardiac involvement - check troponin and ECG before intubation 4
5. Never assume respiratory stability - frequent pulmonary function monitoring is essential 4